New orally active derivatives of artemisinin with high efficacy against multidrug-resistant malaria in mice

Journal of Medicinal Chemistry

Volumn 49, Issue 24, 2006, Pages 7227-7233

  Singh, Chandan ^a   Chaudhary, Sandeep ^a   Puri, Sunil K ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ARTEETHER; DIHYDROARTEMISININ DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG SOLUBILITY; DRUG SYNTHESIS; LIPOPHILICITY; MALARIA; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PARASITEMIA; PLASMODIUM YOELII; TREATMENT DURATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANIMALS; ANTIMALARIALS; ARTEMISININS; DRUG RESISTANCE, MULTIPLE; ISOMERISM; MALARIA; MICE; PLASMODIUM YOELII; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33845366593     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm060826x     Document Type: Article

References (40)

1. CDRI Communication No.: 6999.
2. W. H. O. Drug Inf. Bull. 1999, 13, 9.
3. For reviews on artemisinin and its analogues, see: (a) Klayman, D. L. Qinghaosu (artemisinin): an antimalarial drug from China. Science 1985, 228, 1049-1055.
4. (b) Luo, X. D.; Shen, C. C. The chemistry, pharmacology, and clinical applications of qinghaosu (artemisinin) and its derivatives. Med. Res. Rev. 1987, 7, 29-52.
5. (c) Cumming, J. N.; Ploypradith, P.; Posner, G. H. Antimalarial activity of artemisinin (qinghaosu) and related trioxanes. Adv. Pharmacol. 1997, 37, 2253-297.
6. (d) Bhattacharya, A. K.; Sharma, R. P. Recent developments on the chemistry and biological activity of artemisinin and related antimalarials. Heterocycles 1999, 51, 1681-1745.
7. (e) Borstnik, K.; Paik, I.; Shapiro, T. A.; Posner, G. H. Antimalarial chemotherapeutic peroxides: artemisinin, yingzhaosu A and related compounds. Int. J. Parasitol. 2002, 32, 1661-1667.
8. (f) Ploypradith, P. Development of artemisinin and its structurally simplified trioxane derivatives as antimalarial drugs. Acta Trop. 2004, 89, 329-342.
9. (g) O'Neill, P. M.; Posner, G. H. A Medicinal chemistry perspective on artemisinin and related endoperoxides. J. Med. Chem. 2004, 47, 2945-2964.
10. (a) Asthana, O. P.; Srivastava, J. S.; Valecha, N. Current status of the artemisinin derivatives in the treatment of malaria with focus on arteether. J. Paras. Dis. 1997, 211, 1-12.
11. (b) Jambou, R.; Legrand, E.; Niang, M.; Khim, N.; Lim, P.; Volney, B.; Therese Ekala, M.; Bouchier, C.; Esterre, P.; Fandeur, T.; Mercereau-Puijalon, O. Resistance of Plasmodium falciparum field isolates to in-vitro artemether and point mutations of the SERCA-type PfATPase6. Res. Lett. 2005, 366, 1960-1963.
12. Meshnick, S. R.; Taylor, T. E.; Kamchonwongpaisan, S. Artemisinin and the Antimalarial Endoperoxides: From Herbal Remedy to Targeted Chemotherapy. Microbiol. Rev. 1996, 60, 301-315.
13. (a) Hindley, S.; Ward, S. A.; Storr, R. C.; Searle, N. L.; Bray, P. G.; Park, B. K.; Davies, J.; O'Neill, P. M. Mechanism-Based Design of Parasite-Targeted Artemisinin Derivatives: Synthesis and Antimalarial Activity of New Diamine Containing Analogues. J. Med. Chem. 2002, 45, 1052-1063.
14. (b) Avery, M. A.; Alvim-Gaston, M.; Vroman, J. A.; Wu, B.; Ager, A.; Peters, W.; Robinson, B. L.; Charman, W. Structure-Activity Relationships of the Antimalarial Agent Artemisinin. 7. Direct Modification of (+)-Artemisinin and in Vivo Antimalarial Screening of New, Potential Preclinical Antimalarial Candidates. J. Med. Chem. 2002, 45, 4321-4335.
15. (c) Posner, G. H.; Paik, I.-H.; Sur, S.; McRiner, A. J.; Borstnik, K.; Xie, S.; Shapiro, T. A. Orally Active, Antimalarial, Anticancer, Artemisinin-Derived Trioxane Dimers with High Stability and Efficacy. J. Med. Chem. 2003, 46, 1060-1065.
16. (d) Grellepois, F.; Chorki, F.; Ourevitch, M.; Charneau, S.; Grellier, P.; McIntosh, K. A.; Charman, W. N.; Pradines, B.; Crousse, B.; Bonnet-delpon, D.; Begue, J. P. Orally active Antimalarials: Hydrolytically stable derivatives of 10-Trifluromethyl Anhydrodihydroartemisinin. J. Med. Chem. 2004, 47, 1423-1433.
17. (e) Paik, I.-H.; Xie, S.; Shapiro, T. A.; Labonte, T.; Narducci Sarjeant, A. A.; Baege, A. C.; Posner, G. H. Second Generation, Orally Active, Antimalarial, Artemisinin-Derived Trioxane Dimers with High Stability, Efficacy, and Anticancer Activity J. Med. Chem. 2006, 49(9), 2731-2734.
18. This work has been covered in a patent: Singh, C.; Chaudhary, S.; Puri, S. K. Novel lipophilic ether derivatives of dihydroartemisinin as antimalarials. Indian Patent application. No. 0201 DEL 2004, Filing Date 14-02-2005.
19. Brossi, A.; Venugopalan, B.; Dominquez, G. L.; Yeh, H. J. C.; Flippen, A. J. L.; Buchs, P.; Wo, X. D.; Milhous, W.; Peters, W. Arteether, a New antimalarial drug: synthesis and antimalarial properties. J. Med. Chem. 1988, 31, 645.
20. (a) Peters, W. Techniques for the study of drug response in experimental malaria. In Chemotherapy and drug resistance in malaria; Academic Press: London, 1970; pp 64-136.
21. 16 Mice treated with β-arteether served as positive control.
22. Lin, A. J.; Miller, R. E. Antimalarial activity of new Dihydroartemisinin derivatives. 6. α-Alkylbenzylic Ethers. J. Med. Chem. 1995, 38, 764-770.
23. (a) Singh, C.; Gupta, N.; Puri, S. K. Synthesis of new 6-alkylvinyl/ arylalkylvinyl substituted 1, 2, 4-trioxanes active against multidrug-resistant malaria in mice. Bioorg. Med. Chem. 2004, 12, 5553-5562.
24. (b) Singh, C.; Tiwari, P.; Puri, S. K. Substituted 1,2,4-trioxanes useful as antimalarial agents and a process for the preparation thereof. US Patent 6737438 B2, dated May 18, 2004.
25. (c) Singh, C.; Kanchan, R.; Puri, S. K. Novel substituted 1, 2, 4-trioxanes as antimalarial agents. Indian Patent application. No. 1554 DEL 99, filing date Dec 12, 1999.
26. (a) Craig, P. N. Drug Compendium. In Comprehensive Medicinal Chemistry, 1st ed.; Vol. 6. Mansch, C.; Sammes, P. G., Taylor, J. B., Eds.; Pergamon Press.; Oxford, UK, 1990; pp 237-965.
27. (b) Vennerstrom, J. L.; Arbe-Barnes, S.; Brun, R.; Charman, S. A.; Chiu, F. C. K.; Chollet, J.; Dong, Y.; Dorn, A.; Hunziker, D.; Matile, H.; McIntosh, K.; Padmanilayam, M.; Santo Tomas, J.; Scheurer, C.; Scorneaux, B.; Tang, Y.; Urwyler, H.; Wittlin S.; Charman, W. N. Identification of an antimalarial synthetic trioxolane drug development candidate. Nature (London) 2004, 430, 900-904.
28. (c) Augeri, D. J.; Robl, J. A.; Betebenner, D. A.; Magnin, D. R.; Khanna, A.; Robertson, J. G.; Wang, A.; Simpkins, L. M.; Taunk, P.; Huang, Q.; Han, S.-P.; Abboa-Offei, B.; Cap, M.; Xin, L.; Tao, L.; Tozzo, E.; Welzel, G. E.; Egan, D. M.; Marcinkeviciene, J.; Chang, S. Y.; Biller, S. A.; Kirby, M. S.; Parker, R. A.; Hamann, L. G. Discovery and Preclinical Profile of Saxagliptin (BMS-477118): A Highly Potent, Long-Acting, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes. J. Med. Chem. 2005, 48, 5025-5037.
29. (d) Lund, B. W.; Piu, F.; Gauthier, N. K.; Eeg, A.; Currier, E.; Sherbukhin, V.; Brann, M. R.; Hacksell, U.; Olsson, R. Discovery of a Potent, Orally Available, and Isoform-Selective Retinoic Acid β2 Receptor Agonist. J. Med. Chem. 2005, 48, 7517-7519.
30. (e) Griesbeck, A. G.; El-Idreesy, T. T.; Hoinck, L.-O.; Lexa, J.; Brun, R. Novel spiroanellated 1,2,4-trioxanes with high in vitro antimalarial activities. Bioorg. Med. Chem. Lett. 2005, 15, 595-597.
31. (f) Nguyen, C.; Kasinathan, G.; Leal-Cortijo, I.; Musso-Buendia, A.; Kaiser, M.; Brun, R.; Ruiz-Pérez, L. M.; Johansson, N. G.; González-Pacanowska, D.; Gilbert, I. H. Deoxyuridine Triphosphate Nucleotidohydrolase as a Potential Antiparasitic Drug Target. J. Med. Chem. 2005, 49(19), 5942-5954.
32. (g) Stern, E.; Muccioli, G. G.; Millet, R.; Goossens, J.-F.; Farce, A.; Chavatte, P.; Poupaert, J. H.; Lambert, D. M.; Depreux, P.; Hénichart, J.-P. Novel 4-Oxo-1, 4-dihydroquinoline-3-carboxamide Derivatives as New CB2 Cannabinoid Receptors Agonists: Synthesis, Pharmacological Properties and Molecular Modeling. J. Med. Chem. 2006, 49(1), 70-79.
33. (h) Roberti, M.; Pizzirani, D.; Recanatini M.; Simoni, D.; Grimaudo, S.; Cristina, A. D.; Abbadessa, V.; Gebbia, N.; Tolomeo, M.; Identification of a Terphenyl Derivative that Blocks the Cell Cycle in the G0-G1 Phase and Induces Differentiation in Leukemia Cells. J. Med. Chem. 2006, 49(10), 3012-3018.
34. (i) Qiao, L.; Baumann, C. A.; Crysler, C. S.; Ninan, N. S.; Abad, M. C.; Spurlino, J. C.; DesJarlais, R. L.; Kervinen, J.; Neeper, M. P.; Bayoumy, S. S. Discovery, SAR, and X-ray structure of novel biaryl-based dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. Lett. 2006, 16(1), 123-128.
35. (j) Leban, J.; Kralik, M.; Mies, J.; Baumgartner, R.; Gassen M.; Tasler, S. Biphenyl-4-ylcarbamoyl thiophene carboxylic acids as potent DHODH inhibitors. Bioorg. Med. Chem. Lett. 2006, 16(2), 267-270.
36. (k) Xiang, J. S.; Hu, Y.; Rush, T. S.; Thomason, J. R.; Ipek, M.; Sum, P.-E.; Abrous, L.; Sabatini, J. J.; Georgiadis, K.; Reifenberg, E. Synthesis and biological evaluation of biphenylsulfonamide carboxylate aggrecanase-1 inhibitors. Bioorg. Med. Chem. Lett. 2006, 16(2), 311-316.
37. Compound 7 has been prepared earlier: Lin, A. J.; Lee, M.; Klayman, D. L. Antimalarial Activity of New Water-Soluble Dihydroartemisinin Derivatives. 2. Stereospecificity of the Ether Side Chain. J. Med. Chem. 1989, 32, 1249-1252.
38. Frenkel, Y. V.; Clark, A. D., Jr.; Das, K.; Wang, Y.-H, Lewis, P. J.; Janssen, P. A. J.; Arnold, E. Concentration and pH dependent aggregation of hydrophobic drug molecules and relevance to oral bioavailability. J. Med. Chem. 2005, 48, 1974-1983.
39. (a) 100% suppression of parasitemia means no parasites were detected in 50 oil immersion microscopic fields (parasites if at all present, are below the detection limit). The parasites present below the detection limit can multiply and eventually can be detected during observation on subsequent days. In such cases, though, the drug is providing near 100% suppression of the parasitaemia on day 4 but will not provide full protection to the treated mice in the 28 day survival assay. Multidrug-resistant Plasmodium yoelii nigeriensis used in this study is resistant to chloroquine, mefloquine, and halofantrine. (b) 100% protection means none of the treated mice developed patent infection during the 28 days observation period and hence were recorded as cured. Similarly, 20% protection means only one out of five mice was cured.
40. Puri, S. K.; Singh, N. Azithromycin: antimalarial profile against blood- and sporozite-induced infections in mice and monkeys. Expl. Parasitol. 2000, 94, 8-14.